Navigation Links
Low-Dose Oral Contraceptives May Increase Risk of Pelvic Pain During Sexual Climax
Date:5/3/2013

SAN DIEGO, May 3, 2013 /PRNewswire-USNewswire/ -- Low-dose (low estrogen) oral contraceptives (OCPs) may increase a woman's risk for chronic pelvic pain symptoms (CPPS) and even pain during sexual climax, according to a new study. This study will be presented to reporters at the 108th Annual Scientific Meeting of the American Urological Association (AUA) during a press conference at the San Diego Convention Center, San Diego, CA on May 7 at 11:00 a.m. PDT.

Oral contraceptives have been available in the United States for more than half a century and while considered innocuous today (because of lower doses of estrogen) than even 25 years ago, their effects on conditions such as CPPS are not yet fully understood. Therefore researchers from New York University and Waitemata District Health Board in Auckland, New Zealand conducted a study to compare CPPS between young women who are current OCP users and non-users.

Researchers used data collected from an anonymous, Internet-based survey of women 18-39 years of age within large university populations. The researchers did not include women who were pregnant or had a history of endometriosis or pelvic pain, and gathered demographic data as well as information on the type of OCP, duration of use, and indication for usage. Once data was collected, respondents were sorted into the following groups:

  • Not using an OCP
  • Taking a low-dose of estrogen
  • Taking a normal dose (>20mcg) of estrogen

Additionally, respondents were classified as having CPPS if their total index pain score was greater than or equal to four. The researchers then compared the responses between the groups.

Of the 932 respondents who were eligible for the study, 605 were categorized as non-OCP users and 327 were categorized as OCP users, with 169 using low-dose and 171 using normal dose OCPs. The researchers found significant differences in the incidence of individual pelvic pain symptoms between OCP users and non−users and further differences with low−dose use. Specifically, results showed:

  • Low−dose OCP users were more likely to report pelvic pain symptoms and more likely to have CPPS than non−users (27.1 percent vs. 17.5 percent, p=0.045).
  • Low-dose OCP users had almost twice the incidence of pain or discomfort during or after sexual climax compared to controls, and there was no difference between normal dose OCP users and controls.
  • Normal dose OCP users were less likely to have pelvic pain symptoms than non OCP users.
  • Forty-four percent of respondents reported onset of pain after beginning OCP use and were more likely to fulfill CPPS criteria than those who had symptoms prior to OCP use (62 percent vs. 30.3 percent, p<0.001).

"This study reveals valuable insights into the relationship between oral contraceptives, pelvic pain and how effects may differ depending on hormone dosage," said Dr. Kristene Whitmore , chair of urology and female pelvic medicine and reconstructive surgery and professor of urology and OBGYN at Drexel University College of Medicine. "It also has been recently reported that patients have an increased incidence of vulvodynia when taking low dose OCPs, therefore additional research is needed to determine if the chronic pelvic pain noted in this study is related to vulvar pain or the hormone dosage."

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 19,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.


'/>"/>
SOURCE American Urological Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
2. Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
3. Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
4. Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
5. HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
6. Chindex-Fosun Pharma Joint Venture, Chindex Medical, To Participate in Acquisition of Alma Lasers; Fosun Pharma Increases Investment in Chindex Medical
7. Amgens First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
8. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
9. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
10. Wright, Biomet, Stryker Hip Recall Settlement Funding News: Legal-Bay To Increase Funding Amounts Up to $50K
11. Western European Endoscopic Devices Market to Benefit from Increase in Minimally Invasive Surgeries, Says Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
(Date:4/29/2016)... 2016  In the next ten years, the ... systems dependent on CRTs monitors to those reliant on ... Medical monitors and will automatically sync to existing ... foreseeable benefits to this technological advancement, it also ... to be replaced in order to be LCD ...
(Date:4/29/2016)... , April 29, 2016 ... for Life Sciences, Product Development Capabilities in ... Science Customer Base . Indegene ... today announced the acquisition of Skura Corporation,s life ... leader in adaptive sales enablement technology for life ...
Breaking Medicine Technology:
(Date:5/4/2016)... , ... May 04, 2016 , ... Nike Rugby Camp's ... rugby in San Diego. Willis, founder of Elite Rugby Camps and current Nike Camp ... players every year since 2009. , “I’m excited for our eighth summer here ...
(Date:5/4/2016)... ... 04, 2016 , ... Hight-Doland Insurance Agency’s new community involvement program which serves ... Big Sisters of Southwest Louisiana to help provide positive mentoring for local youth. Donations ... Big Sisters of Southwest Louisiana has been helping to guide the area’s youth for ...
(Date:5/4/2016)... ... May 04, 2016 , ... May kicked off with Melanoma ... United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as well as residents ... on skin safety and health now and in the future. , The dermatology-specific awareness ...
(Date:5/4/2016)... ... May 04, 2016 , ... Momsense, Inc. ... mothers. The company’s patented technology, The Smart Breastfeeding Meter, is designed to monitor ... the technology is now available for purchase at Target.com . , ...
(Date:5/4/2016)... ... ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car rental ... at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses and ... as her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 in ...
Breaking Medicine News(10 mins):